Macrophage and microglial polarization pathways

Macrophage and microglial polarization pathways represent the biochemical cascades that dictate the functional state of myeloid cells in response to their microenvironment. These pathways allow cells to transition between a pro-inflammatory 'M1' phenotype, characterized by the production of cytokines like TNF-alpha and reactive oxygen species, and an anti-inflammatory 'M2' phenotype, which promotes tissue repair and resolution of inflammation (Martinez & Gordon, 2014). In the central nervous system, microglial polarization is a critical factor in the progression of neurodegenerative diseases like Alzheimer's and Parkinson's, where chronic M1 activation leads to neuronal damage (Tang & Le, 2016). Conversely, in oncology, tumor-associated macrophages (TAMs) are often polarized toward an M2-like state that suppresses the anti-tumor immune response and promotes metastasis (Mantovani et al., 2017). Therapeutic targeting of these pathways involves modulating specific receptors and transcription factors, such as Colony stimulating factor 1 receptor (CSF1R), Toll-like receptors (TLRs), and Peroxisome proliferator-activated receptor gamma (PPAR-gamma), to shift the cellular balance toward a phenotype that resolves the underlying pathology (Colonna & Butovsky, 2017). The high degree of plasticity and the existence of intermediate states beyond the binary M1/M2 model present significant challenges for drug development.

Other names

M1/M2 polarizationMacrophage activationMicroglial activationPhenotypic switchingMyeloid cell polarization

Pharmacological modulation of upstream receptors (e.g., CSF1R, TLR4) or downstream transcription factors (e.g., STAT1, STAT6, PPAR-gamma) to shift the functional phenotype of macrophages and microglia from a pathological state to a homeostatic or therapeutic state.